吡格列酮
医学
内科学
心力衰竭
2型糖尿病
胰岛素抵抗
心脏病学
糖尿病
心房颤动
多囊卵巢
内分泌学
胰岛素
作者
David S. H. Bell,Terri Jerkins
摘要
Abstract Pioglitazone improves glycaemic control, not only by lowering insulin resistance, but also by improving beta cell function. Because of the improved beta cell function the glycaemic control that occurs with pioglitazone is prolonged. Pioglitazone has positive effects not only on cardiac risk factors and surrogate measures of cardiovascular disease, it also lowers the incidence of cardiac events in patients with diabetes. The recurrence of transient ischaemic attack and ischaemic stroke is also reduced in non‐diabetic, insulin‐resistant subjects. Utilized at preclinical stages (but not later) of heart failure, pioglitazone improves diastolic function and avoids progression to heart failure. Pioglitazone, through suppression of atrial remodelling, also decreases the incidence of atrial fibrillation. The manifestations of diseases associated with insulin resistance (non‐alcoholic steatohepatitis and polycystic ovary disease) are also improved with pioglitazone. Pioglitazone may possibly improve psoriasis and other dermopathies. Pioglitazone is therefore an inexpensive and efficacious drug for the insulin‐resistant subject with diabetes that is underutilized because of biases that have evolved from the toxicities of other thiazolidinediones.
科研通智能强力驱动
Strongly Powered by AbleSci AI